Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects
Status: | Completed |
---|---|
Conditions: | Gastrointestinal |
Therapuetic Areas: | Gastroenterology |
Healthy: | No |
Age Range: | 18 - 70 |
Updated: | 10/18/2018 |
Start Date: | March 2014 |
End Date: | October 2014 |
A Phase 1, Open-Label, Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Dose of Duvelisib in Subjects With Chronic Hepatic Impairment Compared to Healthy Subjects
To evaluate the pharmacokinetics, safety, and tolerability of IPI-145 when administered to
subjects with chronic hepatic impairment and in matched healthy subjects.
subjects with chronic hepatic impairment and in matched healthy subjects.
This is a nonrandomized, open-label, parallel-group, single oral dose study in subjects with
chronic hepatic impairment and matched (age, sex, weight, BMI) healthy subjects. Subjects
will be enrolled into 1 of 3 groups based on hepatic impairment grade: mild, moderate and
normal hepatic function. An optional severe hepatic impairment group will enroll based on
data from the mild and moderate hepatic impairment groups in comparison to matched healthy
group. All subjects will receive a single oral dose of IPI-145 25 mg.
chronic hepatic impairment and matched (age, sex, weight, BMI) healthy subjects. Subjects
will be enrolled into 1 of 3 groups based on hepatic impairment grade: mild, moderate and
normal hepatic function. An optional severe hepatic impairment group will enroll based on
data from the mild and moderate hepatic impairment groups in comparison to matched healthy
group. All subjects will receive a single oral dose of IPI-145 25 mg.
Inclusion Criteria:
- Men or women of nonchildbearing potential between 18-70 years of age
- Body Mass Index (BMI): 18.0 - 38.0 kg/m2.
- Healthy subjects: in good health, determined by no clinically significant findings
from clinical evaluations
- Hepatic impairment subjects: confirmed hepatic impairment >1 year with etiology of
chronic alcoholism, chronic viral hepatitis (B or C), nonalcoholic steatohepatitis,
autoimmune hepatitis, Wilson disease, alpha-1 antitrypsin deficiency, glycogen storage
diseases, or galactosemia
- Provided written informed consent prior to any study specific procedures
Exclusion Criteria:
- Women of childbearing potential
- Hepatic impairment subjects: fluctuating or rapidly deteriorating hepatic function,
acute hepatitis, variceal bleeding within 8 weeks of screening, a history of
pancreatitis within 8 weeks of screening, evidence of hepatic encephalopathy > Grade
1, current unstable hematologic condition, and/or creatinine clearance < 60 mL/min
- Healthy subjects: positive screening test for hepatitis B surface antigen, or
hepatitis C antibody
- ECG at screening or Day -1 showing QTcF ≥ 450 msec for healthy subjects or > 500 msec
for hepatically impaired subjects
- Evidence of clinically significant medical conditions
- History of gastrointestinal disease or surgery that may affect drug absorption
- Positive or indeterminate QuantiFERON-TB Gold test at screening
- Any active infection at the time of screening or admission
We found this trial at
1
site
Click here to add this to my saved trials